Cargando…
Update on the Management of Uveitic Macular Edema
Uveitic macular edema (ME) is a frequent complication in 8.3% of uveitis patients and is a leading cause of serious visual impairment in about 40% of cases. Despite the numerous available drugs for its treatment, at least a third of patients fail to achieve satisfactory improvement in visual acuity....
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470573/ https://www.ncbi.nlm.nih.gov/pubmed/34575244 http://dx.doi.org/10.3390/jcm10184133 |
_version_ | 1784574234633175040 |
---|---|
author | Teper, Slawomir Jan |
author_facet | Teper, Slawomir Jan |
author_sort | Teper, Slawomir Jan |
collection | PubMed |
description | Uveitic macular edema (ME) is a frequent complication in 8.3% of uveitis patients and is a leading cause of serious visual impairment in about 40% of cases. Despite the numerous available drugs for its treatment, at least a third of patients fail to achieve satisfactory improvement in visual acuity. First-line drugs are steroids administered by various routes, but drug intolerance or ineffectiveness occur frequently, requiring the addition of other groups of therapeutic drugs. Immunomodulatory and biological drugs can have positive effects on inflammation and often on the accompanying ME, but most uveitic randomized clinical trials to date have not aimed to reduce ME; hence, there is no clear scientific evidence of their effectiveness in this regard. Before starting therapy to reduce general or local immunity, infectious causes of inflammation should be ruled out. This paper discusses local and systemic drugs, including steroids, biological drugs, immunomodulators, VEGF inhibitors, and anti-infection medication. |
format | Online Article Text |
id | pubmed-8470573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84705732021-09-27 Update on the Management of Uveitic Macular Edema Teper, Slawomir Jan J Clin Med Review Uveitic macular edema (ME) is a frequent complication in 8.3% of uveitis patients and is a leading cause of serious visual impairment in about 40% of cases. Despite the numerous available drugs for its treatment, at least a third of patients fail to achieve satisfactory improvement in visual acuity. First-line drugs are steroids administered by various routes, but drug intolerance or ineffectiveness occur frequently, requiring the addition of other groups of therapeutic drugs. Immunomodulatory and biological drugs can have positive effects on inflammation and often on the accompanying ME, but most uveitic randomized clinical trials to date have not aimed to reduce ME; hence, there is no clear scientific evidence of their effectiveness in this regard. Before starting therapy to reduce general or local immunity, infectious causes of inflammation should be ruled out. This paper discusses local and systemic drugs, including steroids, biological drugs, immunomodulators, VEGF inhibitors, and anti-infection medication. MDPI 2021-09-14 /pmc/articles/PMC8470573/ /pubmed/34575244 http://dx.doi.org/10.3390/jcm10184133 Text en © 2021 by the author. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Teper, Slawomir Jan Update on the Management of Uveitic Macular Edema |
title | Update on the Management of Uveitic Macular Edema |
title_full | Update on the Management of Uveitic Macular Edema |
title_fullStr | Update on the Management of Uveitic Macular Edema |
title_full_unstemmed | Update on the Management of Uveitic Macular Edema |
title_short | Update on the Management of Uveitic Macular Edema |
title_sort | update on the management of uveitic macular edema |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470573/ https://www.ncbi.nlm.nih.gov/pubmed/34575244 http://dx.doi.org/10.3390/jcm10184133 |
work_keys_str_mv | AT teperslawomirjan updateonthemanagementofuveiticmacularedema |